Aside from the possibility of using these targets to develop new drugs for retinal diseases, targeting pyroptotic cell death pathways can also have an impact on existing therapies for retinal diseases, namely anti-VEGF. This evidence concerns the gene VEGFA and Abnormal retinal morphology.